Yannan Hu

Overexpression of CENP-H as a novel prognostic biomarker for human hepatocellular carcinoma progression and patient survival

Guifang Lu, Tao Shan, Shuixiang He et al. · Oncology Reports · 2013 · 24 citations · Full text

Medicine, Molecular Biology, Oncology +16

Front-Line Daratumumab-VTd Versus Standard-of-Care in ASCT-Eligible Multiple Myeloma: Matching-Adjusted Indirect Comparison

Philippe Moreau, Benjamin Hébraud, Thierry Façon et al. · Immunotherapy · 2020 · 17 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

A matching-adjusted indirect comparison of the efficacy of elranatamab versus teclistamab in patients with triple-class exposed/refractory multiple myeloma

Isha Mol, Yannan Hu, Thomas W. LeBlanc et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2024 · 16 citations · Full text

Medicine, Oncology, Pharmacology +15

A matching-adjusted indirect comparison of the efficacy of elranatamab versus physician’s choice of treatment in patients with triple-class exposed/refractory multiple myeloma

Isha Mol, Yannan Hu, Thomas W. LeBlanc et al. · Current Medical Research and Opinion · 2023 · 12 citations

Medicine, Pharmacology, Pharmacotherapy +17